FDA Expected to Approve New Diet Drug

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

(CNN) — The U.S. Food and Drug Administration is expected to approve a new prescription diet drug called Qnexa on Tuesday.

The medication produced dramatic weight loss in clinical trials, but some are concerned over potential side effects, including increased heart rate, birth defects and other issues.

If approved, Qnexa (pronounced kyoo-NEX-uh) would become the second diet drug approved this year. The FDA approved a weight-loss pill called Belviq on June 27.

Patients in clinical trials experienced more dramatic weight loss with Qnexa than with Belviq. On Qnexa, patients went from an average 227 pounds to 204 pounds; on Belviq, the average weight dropped from 220 to 207.

But some consumer advocates worry the weight loss comes with a price. Some patients in the clinical trial suffered an increased heart rate and a condition called metabolic acidosis, which can lead to hyperventilation, fatigue, and anorexia.

Concerns have also been raised about birth defects. One of the ingredients in Qnexa is topiramate, an anti-convulsant that has been linked to birth defects such as cleft lip and cleft palate in babies born to women who have taken it for migraines or seizures. Qnexa’s other ingredient is phentermine, an appetite suppressant.

“Our belief is that women will be invited to compelling advertising and marketing messages to experiment on themselves with a drug that has some effectiveness with healthy weight loss, but possible serious risks,” said Cindy Pearson, executive director of the National Women’s Health Network.

Qnexa’s manufacturer, Vivus Inc., says the drug helped lower blood pressure and cholesterol levels in obese people, and people taking it were less likely to get Type 2 diabetes.

“Obesity is not being adequately addressed by diet and lifestyle changes or currently available therapies,” the company said in a statement. “The need for new options is urgent, particularly non-surgical options.”

The FDA is expected to approve Qnexa only for obese people, or for overweight people with a body mass index greater than 27 who also suffer from weight-related conditions like hypertension and diabetes.

Doctors, however, are free to prescribe the drug to anyone, and there are concerns physicians will open “pill mills” and prescribe Qnexa to people who just want to lose a few pounds. That’s what happened in the 1990s with fen-phen, another diet drug combination that includes phentermine.

Vivus will at first offer the pill only through mail order so doctors can’t sell it directly, said Dr. Barbara Troupin, Vivus’ vice president of scientific communications and risk management.

“There will not be dispensing from doctors’ offices,” she said.”Seeing that issue and what has happened in fad and diet drugs in the past, that is not a path that we’re going to be taking.”

The 4,430 overweight and obese patients in the Qnexa studies experienced various levels of weight loss. About half of patients on the recommended dose lost 10% of their weight, while four-fifths lost 5%. That amounts to about 12 pounds for a 227-pound person.

Meg Evans, one of the patients, lost even more weight. She started out at 230 pounds and lost 48 pounds her first year on the drug and another two pounds the second year.

“I loved it,” she told CNN. “I wasn’t hungry. I almost had to remind myself to eat.”

At 5 feet 9 inches tall, Evans, now 63, describes herself as having been “Twiggy-like” in college, weighing just 120 pounds. Then she gained weight after having four children. An avid cook and eater, she said the drug made it easier to resist tempting foods.

“If I saw a chocolate chip cookie, it was easy enough for me to say, ‘I’m not really hungry. I can pass on it,'” Evans said.

She said the weight came off gradually, about four pounds a month, and her blood pressure went down almost immediately.

Despite the pill’s apparent ability to help people lose weight, some critics say it should never have been approved because of the possible side effects.

“I believe that if the public were to ‘buy’ (Qnexa) after FDA approval, it would run the risk of severe, even fatal, consequences from another diet lemon,” Dr. Michael Lauer writes in Annals of Internal Medicine, also noting that the drug led to a slight increase in heart rates.

In February, Lauer was one of two FDA advisory committee members who voted against Qnexa’s approval in a 20-2 decision.

The FDA and Vivus both acknowledge that the three clinical trials meant to measure Qnexa’s safety and effectiveness were not designed to properly assess cardiovascular risk.

Vivus says that a study on the drug’s cardiovascular effects will be done after the drug’s approval.

Despite the label’s warning that women of childbearing age should use birth control while on Qnexa, there are concerns that women will still get pregnant while on the drug.

In the drug-maker’s two-year clinical trial, 34 women on Qnexa became pregnant, even though they were told repeatedly to use contraception. No birth defects happened in those pregnancies, according to the company.

Previous clinical trials of topiramate, one of the ingredients in Qnexa, have shown a risk of about five birth defects for every 1,000 pregnancies.

Comparing the anti-obesity drug to treatments for other chronic diseases, Troupin says patients will likely need to continue taking Qnexa long-term, though the new drug is not expected to be widely covered by health insurance plans.

Evans, the patient who lost 50 pounds on the drug, said she’s gained back about 20 pounds since the clinical trial ended two years ago, and looks forward to going on Qnexa once it’s approved, even though it can have side effects.

“There are side effects to everything,” she said.

She added that the drug wasn’t the only reason she lost the weight. She said weekly counseling on nutrition and exercise were a big factor, too. The counselor helped her change her diet — choosing a salad for lunch instead of a burger, forgoing pasta and potatoes at dinner — and encouraged her to walk a few times a week in addition to her regular exercise as goalie in a women’s soccer league.

“Before the medicine I had been telling the girls they’d have to find a new goalie because I couldn’t dive for the ball like I did before,” she said. “Then I lost the weight and I was diving and bouncing back up and having a great old time again.”

™ & © 2012 Cable News Network, Inc., a Time Warner Company. All rights reserved.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.